Debra Durso-Bumpus is CPO at Blueprint Medicines Corp (BPMC). They have made 13 open-market trades across 1 company since 2020, most recently 2025-07-17.
CIK 0001802970
Unrated. We grade insiders only on stock they chose to buy on the open market. Grants, option exercises and vesting say nothing about timing, so they don't count — which is why someone can file often and still have no grade. It isn't a bad sign: unrated buys beat every graded tier below A.
0 open-market purchases, against 13 sales. Too few scored purchases to measure a record yet.
| Ticker | Shares | Value |
|---|---|---|
| BPMC | 70,959 | $9.2M |
Shares reported on the most recent Form 4, priced at the 2025-07-21 close.
| Ticker | Type | Traded | Filed | Price | Value | 7d Stock | 30d Stock | 90d Stock |
|---|---|---|---|---|---|---|---|---|
| BPMC | SELL | 2025-03-05 | 2025-03-07 | $88.80 | $916K | +5.7% | -6.3% | +49.4% |
| BPMC | SELL · 10b5-1 | 2024-07-03 | 2024-07-08 | $111.27 | $2.4M | -1.6% | -21.2% | -22.5% |
| BPMC | SELL · 10b5-1 | 2024-06-28 | 2024-07-02 | $111.15 | $37K | +8.2% | -9.2% | -16.2% |
| BPMC | SELL | 2024-06-21 | 2024-06-25 | $104.19 | $15.4M | +9.7% | +7.2% | -15.1% |
| BPMC | SELL | 2024-03-07 | 2024-03-11 | $90.69 | $924K | +1.0% | +1.5% | +16.7% |
| BPMC | SELL | 2023-03-06 | 2023-03-08 | $45.69 | $285K | +3.2% | -3.4% | +32.1% |
| BPMC | SELL | 2022-08-24 | 2022-08-26 | $75.11 | $376K | +7.6% | -12.6% | -37.8% |
| BPMC | SELL | 2022-03-03 | 2022-03-08 | $58.59 | $297K | +17.5% | +23.4% | +4.6% |
| BPMC | SELL | 2021-11-01 | 2021-11-03 | $113.32 | $992K | +3.3% | -15.4% | -29.0% |
| BPMC | SELL | 2021-09-23 | 2021-09-27 | $110.01 | $187K | -6.2% | -0.8% | +5.1% |
| BPMC | SELL | 2021-03-04 | 2021-03-05 | $86.69 | $284K | +10.7% | +4.9% | -9.4% |
| BPMC | SELL | 2020-09-23 | 2020-09-25 | $90.02 | $171K | +12.5% | +16.8% | +39.3% |
| BPMC | SELL | 2020-06-22 | 2020-06-24 | $80.07 | $368K | +1.5% | -1.9% | +14.7% |
| BPMC | SELL | 2020-06-18 | 2020-06-22 | $75.18 | $376K | -0.5% | -1.4% | -2.7% |
| BPMC | SELL | 2020-03-09 | 2020-03-11 | $51.94 | $22K | +6.0% | +32.0% | +51.7% |
Grouped by shared companies and similar filing behaviour. This is a similarity measure, not a ranking or a performance signal.